Development of Rutin nanosuspension decorated transdermal patches using Box-Behnken approach
International Journal of Drug Delivery Technology · 17.06.2026 · 16 (54s)
DOI: 10.25258/ijddt.16.54s.6 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 17.06.2026. Verfasst von Vivek H. Rathod und 2 weiteren Autor:innen.
Abstract (Originalsprache)
The goal of the current study is to create and improve transdermal patches that contain Rutin (RTN) nanosuspensions (NSPs). The goal of NSPs is to make hydrophobic actives more soluble. To ensure RTN's identity and necessary formulation elements, including λmax determination, FT-IR spectroscopic analysis, standard calibration curve, and saturation solubility, preformulation investigations were carried out. These studies guaranteed RTN's identity, purity, and compatibility. NSPs were made utilizing the Box-Behnken design in batches using the precipitation process. Particle size, zeta potential, and drug content were the dependent variables; poloxomer and sodium lauryl sulfate concentrations and homogenization speed were independent parameters. Particle size and zeta potential, drug content, drug loading efficiency, SEM, and in vitro dissolution experiments were all conducted on the formulated NSP batches of RTN. According to the results, NSPs from RTN batch B5 (600 mg poloxomer, 550 mg SLS, and 7000 rpm) were optimal and should be used going forward. The highest cumulative percentage of medication dissolved (99.36%) was found in RTN NSP (Batch S2). PVP, an ethyl cellulose mixture, dibutyl phthalate as a plasticizer, and oleic acid as a penetration enhancer were used to create transdermal patches utilizing an improved batch of RTN NSPs. Physical appearance, folding durability, film thickness, drug content, tensile strength, SEM, in vitro drug release testing, and ex vivo drug diffusion studies were among the evaluation procedures performed on these patch batches. All transdermal patches were shown to be capable of maintaining the drug's release from formulation. In 12 hours, RTN formulation P6 demonstrated 99.23 ± 0.43% drug release. Sustained drug release is resulted by variable quantities of oleic acid, a permeability enhancer, according to the findings of in-vitro and ex-vivo investigations of various batches. Better sustained release was demonstrated by formulations with 5% oleic acid. After three months of expedited stability testing, it was discovered that the improved transdermal patches of RTN and RTN were stable.
Zitieren
APA
Rathod, V. H., Sathe, B. S., & Khathuriya, R. (2026). Development of Rutin nanosuspension decorated transdermal patches using Box-Behnken approach. International Journal of Drug Delivery Technology, 16(54s). https://doi.org/10.25258/ijddt.16.54s.6
Vancouver
Rathod VH, Sathe BS, Khathuriya R. Development of Rutin nanosuspension decorated transdermal patches using Box-Behnken approach. International Journal of Drug Delivery Technology. 2026;16(54s). doi:10.25258/ijddt.16.54s.6
BibTeX
@article{Rathod2026,
author = {Rathod, Vivek H. and Sathe, Bhushankumar S. and Khathuriya, Rajesh},
title = {Development of Rutin nanosuspension decorated transdermal patches using Box-Behnken approach},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {54s},
doi = {10.25258/ijddt.16.54s.6}
}
EUVIMED